Some recent studies have confirmed that LDL-C is the primary intervention target for lipid-lowering therapy. Therefore, patients should pay more attention to blood lipid indicators such as LDL-C and undergo regular monitoring and risk assessment. High risk groups need to control the level of LDL-C more strictly and actively treat basic diseases (such as hypertension and diabetes) to reduce the risk of cardiovascular events. When necessary, under the guidance of a doctor, one can adhere to long-term and scientific use of optimized drugs to control LDL-C.
It is reported that PCSK9 inhibitors are currently the most effective drugs for reducing LDL-C. They are mainly administered subcutaneously, with cycles ranging from two weeks to six months, and can effectively, safely, and sustainably reduce LDL-C.
At present, many patients have the misconception that "once their blood lipids have reached the standard, there is no need to take medication again". We have encountered some patients in clinical practice, especially young patients. After doctors place stents to solve their angina or myocardial infarction problems, they will stop taking medication on their own, including lipid-lowering drugs. After stopping medication, cardiovascular events may occur again. Huang Dong frankly stated that lipid-lowering treatment is a "long-term battle". Due to the continuous synthesis of cholesterol in the human body, if patients stop or reduce their medication on their own, LDL-C levels may rise again, leading to vascular stenosis, blockage, and triggering diseases such as myocardial infarction and cerebral infarction.
In addition, as ASCVD is a progressive disease, unstable plaques may still exist in the blood vessels even after stent implantation, and hyperlipidemia increases the risk of plaque rupture and thrombosis, thereby increasing the risk of cardiovascular events. Adhering to long-term scientific and standardized lipid-lowering treatment is extremely important for stabilizing bad cholesterol levels and reducing the occurrence of cardiovascular high-risk events, "said Huang Dong.
Huang Dong emphasized the need to strengthen long-term standardized management of blood lipids in ASCVD patients from the beginning of admission. ASCVD patients urgently need effective and sufficient intensified lipid-lowering therapy to help them further reduce LDL-C levels and thus lower the risk of cardiovascular events. The current lipid-lowering treatment rate and compliance rate of ASCVD patients still need to be improved, and traditional drugs such as statins are still the main blood lipid management drugs in many grassroots areas. "This expert bluntly stated that statins have the advantages of convenience and effectiveness, but some people have contraindications to using statins and may need to use non statins.
